On Nov 26, major Wall Street analysts update their ratings for $BridgeBio Pharma (BBIO.US)$, with price targets ranging from $45 to $55.
Goldman Sachs analyst Paul Choi maintains with a buy rating, and adjusts the target price from $50 to $55.
BofA Securities analyst Jason Zemansky maintains with a buy rating, and maintains the target price at $45.
Citi analyst David Lebowitz maintains with a buy rating, and maintains the target price at $45.
UBS analyst Eliana Merle maintains with a buy rating, and adjusts the target price from $47 to $54.
Evercore analyst Cory Kasimov maintains with a buy rating, and maintains the target price at $45.
Furthermore, according to the comprehensive report, the opinions of $BridgeBio Pharma (BBIO.US)$'s main analysts recently are as follows:
The FDA's approval of BridgeBio's stabilizer acoramidis as Attruby for ATTR-CM, coming before the anticipated November 29 PDUFA deadline, was celebrated as a significant achievement, marking the company's transition into a commercial entity with an optimal label. The potential for ATTR-CM remains, according to analysts, still largely underestimated.
Here are the latest investment ratings and price targets for $BridgeBio Pharma (BBIO.US)$ from 10 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月26日，多家華爾街大行更新了$BridgeBio Pharma (BBIO.US)$的評級，目標價介於45美元至55美元。
高盛集團分析師Paul Choi維持買入評級，並將目標價從50美元上調至55美元。
美銀證券分析師Jason Zemansky維持買入評級，維持目標價45美元。
花旗分析師David Lebowitz維持買入評級，維持目標價45美元。
瑞士銀行分析師Eliana Merle維持買入評級，並將目標價從47美元上調至54美元。
Evercore分析師Cory Kasimov維持買入評級，維持目標價45美元。
此外，綜合報道，$BridgeBio Pharma (BBIO.US)$近期主要分析師觀點如下：
以下爲今日10位分析師對$BridgeBio Pharma (BBIO.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
